A recent meta-analysis issued in the journal ‘Vaccine’ comprising 629,093 patients demonstrated that the administration of coronavirus disease 2019 vaccination before the SARS-CoV-2 infection was linked with a reduced likelihood of long COVID, particularly after the second dose. This systematic review and meta-analysis by Atsuyuki Watanabe et al. was performed to find the link between the COVID-19 vaccine and long COVID.

A search was done to recognize the prospective trials and observational studies which compared patients with and without vaccination before being infected with COVID. Studies describing the symptomatic variations of ongoing long COVID following vaccination in people with a history of COVID infection were also considered. Odds ratios were pooled utilizing a random-effects model for each result.

A total of twelve studies were included:

• 6 observational studies with 536,291 unvaccinated and 84,603 vaccinated (before being infected) patients; mean age of 41.2 to 66.6 years; % of females- 9.0 to 67.3%
• 6 observational studies involving 8,199 long COVID patients who were administered the vaccine after being infected; mean age of 40 to 53.5 years; % of females- 22.2 to 85.9%

Two-dose vaccination was linked with reduced long COVID risk along with persistent tiredness and pulmonary illness than no vaccination and one-dose. About 54.4% of people did not express symptomatic changes after the vaccination on the other hand, 20.3% had improved symptoms after 2-6 six months of COVID-19 vaccination in people who were enduring long COVID symptoms. Hence, vaccination prior to SARS-CoV-2 disease can be suggested to minimize long COVID syndrome.